Benralizumab Outcomes in Patients with Severe Eosinophilic Asthma Treated in Real-Life Settings: Results of the BREEZE Study in 5 Countries From Central Eastern Europe and Baltics
Our findings indicate clinically meaningful benefits of benralizumab across multiple geographies and various subgroups of patients with SEA.
Authors
- Gabriela Teodorescu (ORCID: https://orcid.org/0000-0003-0880-3425)
- Kęstutis Malakauskas (ORCID: https://orcid.org/0000-0001-9141-2884)
- Zsuzsanna Csoma
- Maria Staevska (ORCID: https://orcid.org/0000-0002-9154-303X)
- Florin Dumitru Mihaltan (ORCID: https://orcid.org/0000-0002-5936-9545)
- Norbert Pauk
- Béla Irás
- Jūratė Baukienė
Institutions
- Lithuanian University of Health Sciences (LT)
- Carol Davila University of Medicine and Pharmacy (RO)
- Charles University (CZ)
- Medical University of Sofia (BG)
- AstraZeneca (Brazil) (BR)
- Lithuanian Geological Survey (LT)
- AstraZeneca (Poland) (PL)
- Országos Korányi Tbc és Pulmonológiai Intézet (HU)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/jaa.s503048
- Citations
- 6
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 6.99
Funders
- AstraZeneca